QualityCounts.com
Use this link for 5% off at iHerb.
To address the growing use of ad blockers we now use affiliate links to sites like Amazon.com, streaming services, and others. Affiliate links help sites like QualityCounts.com stay open. Affiliate links cost you nothing but help me support my family. We do not allow paid reviews on this site. As an Amazon Associate I earn from qualifying purchases.
Home | Catalog | Women's short-sleeve t-shirts | Men's long-sleeve t-shirts | Men's short-sleeve t-shirts |
Sweatshirts | Hoodies | Women's long-sleeve t-shirts | Women's classic fit | Men's classic fit

Home iHerb ReliableRx Amazon.com Contact
 Sign-up for newsletter 
 Newsletter Archive
 Newsletter via RSS Feed
 Research on Supplements
 Health Conditions
 Anti-aging Recommendations
 Insulin and Aging
 QualityCounts.com in Time
 Longevity Affiliates:
 iHerb
 Canva.com
 Printful (Make your own t-shirt) (video)
 Amazon.com
 T-shirts
 

Home > Health Conditions > Diabetes > Jardiance (empagliflozin)

Jardiance (empagliflozin)

Related Topics:

News & Research:

  • Which Antidiabetic Drug Class is Most Renoprotective? - Medscape, 12/2/20 - "All three of the newer drug classes performed better than the sulfonylureas. Both SGLT2i and GLP-1a offered greater renoprotection than DPP-4i, but neither was notably better than the other, according to the analysis. These findings held for patients at various levels of early and advanced chronic kidney disease and were independent of whether the patients were taking metformin" - Note: Jardiance is a SGLT2 inhibitor.
  • SCORED and FIDELIO-DKD: Time for Cardiologists to Help, Not Hurt, the Kidney - Medscape, 11/20/20 - 20 minute video on empagliflozin (Jardiance).  I doubt if most cardiologists are even aware of this yet. - "In terms of heart failure with reduced EF, these are really well-tolerated medicines. I've been using dapagliflozin and empagliflozin in my patients and found them to have good clinical outcomes and to be clinically well tolerated, with minimal side effects"
  • Diabetes drug can treat and reverse heart failure and reduce hospitalizations - Science Daily, 11/16/20 - "Empagliflozin, a recently developed diabetes drug ... this medication can improve the heart's size, shape, and function, leading to better exercise capacity and quality of life, which will reduce hospitalizations for heart failure patients" - Note:  It's a $500/month medication.
  • EMPEROR-Reduced: Empagliflozin's HFrEF Benefit Holds Steady on Top of Sacubitril/Valsartan - Medscape, 10/7/20 - "When there are two very effective treatments, it's common for people to ask: Which should I use?' The goal of my presentation was to emphasize that the answer is both. We shouldn't choose between neprilysin inhibition [sacubitril inhibits the enzyme neprilysin] and SGLT2 [sodium-glucose transporter 2] inhibition; we should use both"

Abstracts:

  • Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications - Hypertens Res 2020 Dec 14 - "metformin blunts the SGLT2i-induced decrease in eGFR, but coadministration of RASis ameliorates this response. Furthermore, the inability of CCBs to modify the SGLT2i-induced reduction in eGFR suggests that the SGLT2i-induced renal microvascular action is mediated predominantly by postglomerular vasodilation rather than preglomerular vasoconstriction" - Note:  Normal eGFR is >60.  I threw this in because the diabetes medication and SGLT2 inhibitor Jardiance (empagliflozin) is also being used to help repair the heart in heart failure patients.
  • Randomized Trial of Empagliflozin in Non-Diabetic Patients with Heart Failure and Reduced Ejection Fraction - J Am Coll Cardiol 2020 Nov 9 - "Empagliflozin administration to non-diabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life when compared with placebo. Our observations strongly support a role for SGLT2 inhibitors in the treatment of HFrEF patients independently of their glycemic status"